Pain in neuromyelitis optica-prevalence, pathogenesis and therapy

Nature Reviews Neurology

Volumn 10, Issue 9, 2014, Pages 529-536

  Bradl, Monika ^a   Kanamori, Yoko ^b   Nakashima, Ichiro ^b   Misu, Tatsuro ^b   Fujihara, Kazuo ^b   Lassmann, Hans ^a   Sandkühler, Jürgen ^a  

^a Medical University of Vienna   (Austria)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINOCYCLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROGESTERONE; REMIFENTANIL;

ANALGESIA; ASTROCYTE; CELL DAMAGE; DRUG MEGADOSE; HUMAN; MYELOOPTIC NEUROPATHY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW;

HUMANS; NEUROMYELITIS OPTICA; PAIN; PAIN MANAGEMENT; PREVALENCE;

EID: 84908096180     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.129     Document Type: Review

References (89)

1. Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J. & Weinshenker, B. G. The spectrum of neuromyelitis optica. Lancet Neurol. 6, 805-815 (2007).
2. Papadopoulos, M. C. & Verkman, A. S. Aquaporin water channels in the nervous system. Nat. Rev. Neurosci. 14, 265-277 (2013).
3. Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364, 2106-2112 (2004).
4. Jarius, S. & Wildemann, B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: A critical review of the literature. Brain Pathol. 23, 661-683 (2013).
5. Bradl, M. et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66, 630-643 (2009).
6. Bennett, J. L. et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 66, 617-629 (2009).
7. Kinoshita, M. et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 386, 623-627 (2009).
8. Saadoun, S. et al. Intra-cerebral injection of neuromyelitis optica imunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133, 349-361 (2010).
9. Bradl, M. & Lassmann, H. Experimental models of neuromyelitis optica. Brain Pathol. 24, 74-82 (2014).
10. Sato, D. K., Lana-Peixoto, M. A., Fujihara, K. & de Seze, J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: Evolution and current status. Brain Pathol. 23, 647-660 (2013).
11. Kanamori, Y. et al. Pain in neuromyelitis optica and its effect on quality of life: A cross-sectional study. Neurology 77, 652-658 (2011).
12. Qian, P. et al. Association of neuromyelitis optica with severe and intractable pain. Arch. Neurol. 69, 1482-1487 (2012).
13. Zhao, S., Mutch, K., Elsone, L., Nurmikko, T. & Jacob, A. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult. Scler. http://dx.doi.org/10.1177/1352458514522103.
14. Pellkofer, H. L. et al. The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica. PLoS ONE 8, e71500 (2013).
15. Kim, S. M., Go, M. J., Sung, J. J., Park, K. S. & Lee, K. W. Painful tonic spasm in neuromyelitis optica: Incidence, diagnostic utility, and clinical characteristics. Arch. Neurol. 69, 1026-1031 (2012).
16. Evangelopoulos, M. E. et al. Neuromyelitis optica spectrum disease with positive autoimmune indices: A case report and review of the literature. Case Rep. Med. 2011, 393568 (2011).
17. Elsone, L. et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult. Scler. 19, 475-479 (2013).
18. Milligan, E. D. & Watkins, L. R. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 10, 23-36 (2009).
19. Marchand, F., Perretti, M. & McMahon, S. B. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 6, 521-532 (2005).
20. Xanthos, D. N. & Sandkühler, J. Neurogenic neuroinflammation: Inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci. 15, 43-53 (2014).
21. Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and molecular mechanisms of pain. Cell 139, 267-284 (2009).
22. Lu, Y. & Perl, E. R. Selective action of noradrenaline and serotonin on neurones of the spinal superficial dorsal horn in the rat. J. Physiol. 582, 127-136 (2007).
23. Sandkühler, J. Models and mechanisms of hyperalgesia and allodynia. Physiol. Rev. 89, 707-758 (2009).
24. Lucchinetti, C. F. et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125, 1450-1461 (2002).
25. Misu, T. et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in the lesions of neuromyelitis optica. Acta Neuropathol. 125, 815-827 (2013).
26. Lucchinetti, C. F. et al. The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica. Brain Pathol. 24, 83-97 (2014).
27. Jarius, S. et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J. Neuroinflammation 9, 14 (2012).
28. Wingerchuk, D. M., Hogancamp, W. F., O'Brien, P. C. & Weinshenker, B. G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53, 1107-1114 (1999).
29. Collongues, N. et al. Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology 74, 736-742 (2010).
30. Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F. & Weinshenker, B. G. Revised diagnostic criteria for neuromyelitis optica. Neurology 66, 1485-1489 (2006).
31. Nakamura, M. et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J. Neurol. 255, 163-170 (2008).
32. Roemer, S. F. et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130, 1194-1205 (2007).
33. Misu, T., Fujihara, K., Nakashima, I., Sato, S. & Itoyama, Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65, 1479-1482 (2005).
34. Hinson, S. R. et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69, 2221-2231 (2007).
35. Rossi, A., Ratelade, J., Papadopoulos, M. C., Bennett, J. L. & Verkman, A. S. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia 60, 2027-2039 (2012).
36. Hinson, S. R. et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 205, 2473-2481 (2008).
37. Marignier, R. et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 133, 2578-2591 (2010).
38. Matsuoka, T., Suzuki, S. O., Suenaga, T., Iwaki, T. & Kira, J. Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol. 21, 516-532 (2011).
39. Matsushita, T. et al. Astrocytopathy in neuromyelitis optica, multiple sclerosis and Balo's disease [Japanese]. Rinsho Shinkeigaku 51, 898-900 (2011).
40. Sharma, R. et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol. 120, 223-236 (2010).
41. Parratt, J. D. & Prineas, J. W. Neuromyelitis optica: A demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult. Scler. 16, 1156-1172 (2010).
42. Nishiyama, S. et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72, 1960-1961 (2009).
43. Uzawa, A., Masahiro, M. & Kuwabara, S. Cytokines and chemokines in neuromyelitis optica: Pathogenetic and therapeutic implications. Brain Pathol. 24, 67-73 (2014).
44. Olechowski, C. J., Truong, J. J. & Kerr, B. J. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 141, 156-164 (2009).
45. Gruber-Schoffnegger, D. et al. Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord lamina I by TNF-α and IL-1β is mediated by glial cells. J. Neurosci. 33, 6540-6551 (2013).
46. Park, C. K. et al. Resolving TRPV1-and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J. Neurosci. 31, 15072-15085 (2011).
47. Ikeda, H. et al. Synaptic amplifier of inflammatory pain in the spinal dorsal horn. Science 312, 1659-1662 (2006).
48. Drdla, R., Gassner, M., Gingl, E. & Sandkühler, J. Induction of synaptic long-term potentiation after opioid withdrawal. Science 325, 207-210 (2009).
49. Meng, X. et al. Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model. Pain 154, 294-305 (2013).
50. Nakatsuka, T., Tsuzuki, K., Ling, J. X., Sonobe, H. & Gu, J. G. Distinct roles of P2X receptors in modulating glutamate release at different primary sensory synapses in rat spinal cord. J. Neurophysiol. 89, 3243-3252 (2003).
51. Hansen, R. R. & Malcangio, M. Astrocytes-multitaskers in chronic pain. Eur. J. Pharmacol. 716, 120-128 (2013).
52. Donnelly-Roberts, D., McGaraughty, S., Shieh, C. C., Honore, P. & Jarvis, M. F. Painful purinergic receptors. J. Pharmacol. Exp. Ther. 324, 409-415 (2008).
53. Jarius, S. & Wildemann, B. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 6, 383-392 (2010).
54. Moga, D., Hof, P. R., Vissavajjhala, P., Moran, T. M. & Morrison, J. H. Parvalbumin-containing interneurons in rat hippocampus have an AMPA receptor profile suggestive of vulnerability to excitotoxicity. J. Chem. Neuroanat. 23, 249-253 (2002).
55. Zeilhofer, H. U., Wildner, H. & Yevenes, G. E. Fast synaptic inhibition in spinal sensory processing and pain control. Physiol. Rev. 92, 193-235 (2012).
56. Coull, J. A. et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438, 1017-1021 (2005).
57. Susser, E., Sprecher, E. & Yarnitsky, D. Paradoxical heat sensation in healthy subjects: Peripherally conducted by Ad or C fibres? Brain 122, 239-246 (1999).
58. Sigel, E. et al. The major central endocannabinoid directly acts at GABAA receptors. Proc. Natl Acad. Sci. USA 108, 18150-18155 (2011).
59. Kallendrusch, S. et al. Intrinsic up-regulation of 2-AG favors an area specific neuronal survival in different in vitro models of neuronal damage. PLoS ONE 7, e51208 (2012).
60. Martinez-Hernandez, A., Bell, K. P. & Norenberg, M. D. Glutamine synthetase: Glial localization in brain. Science 195, 1356-1358 (1977).
61. Albrecht, J., Sidoryk-Wegrzynowicz, M., Zielinska, M. & Aschner, M. Roles of glutamine in neurotransmission. Neuron Glia Biol. 6, 263-276 (2010).
62. Behbehani, M. M. Functional characteristics of the midbrain periaqueductal gray. Prog. Neurobiol. 46, 575-605 (1995).
63. Kremer, L. et al. Brainstem manifestations in neuromyelitis optica: A multicenter study of 258 patients. Mult. Scler. http://dx.doi.org/10.1177/1352458513507822.
64. Verkman, A. S., Phuan P.-W., Asavapanumas, N. & Tradtrantip, L. Biology of AQP4 and anti-AQP4 antibody: Therapeutic implications for NMO. Brain Pathol. 23, 684-695 (2013).
65. Kumar, A. & Loane, D. J. Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. Brain Behav. Immun. 26, 1191-1201 (2012).
66. Wang, X. et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc. Natl Acad. Sci. USA 109, 6325-6330 (2012).
67. Wallace, M. S., Lam, V. & Schettler, J. NGX426, an oral AMPA-kainate antagonist, is effective in human capsaicin-induced pain and hyperalgesia. Pain Med. 13, 1601-1610 (2012).
68. Volpi, C., Fazio, F. & Fallarino, F. Targeting metabotropic glutamate receptors in neuroimmune communication. Neuropharmacology 63, 501-506 (2012).
69. Sandkühler, J. & Lee, J. How to erase memory traces of pain and fear. Trends Neurosci. 36, 343-352 (2013).
70. Drdla-Schutting, R., Benrath, J., Wunderbaldinger, G. & Sandkühler, J. Erasure of a spinal memory trace of pain by a brief, high-dose opioid administration. Science 335, 235-238 (2012).
71. Taira, T. et al. A new approach to control central deafferentation pain: Spinal intrathecal baclofen. Stereotact. Funct. Neurosurg. 65, 101-105 (1995).
72. Dykstra, D., Stuckey, M., DesLauriers, L., Chappuis, D. & Krach, L. Intrathecal baclofen in the treatment of spasticity. Acta Neurochir. Suppl. 97, 163-171 (2007).
73. Rog, D. J., Nurmikko, T. J., Friede, T. & Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 27, 812-819 (2005).
74. Hunt, S. P. & Mantyh, P. W. The molecular dynamics of pain control. Nat. Rev. Neurosci. 2, 83-91 (2001).
75. Pittock, S. J. et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol. 63, 964-968 (2006).
76. Kitic, M. et al. Intrastriatal injection of interleukin 1 β triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol. Commun. 1, 5 (2013).
77. Uzawa, A. et al. Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. Mult. Scler. 16, 1443-1452 (2010).
78. Uzawa, A. et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J. Neurol. 256, 2082-2084 (2009).
79. Icoz, S. et al. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int. J. Neurosci. 120, 71-75 (2010).
80. Wei, X. H. et al. The up-regulation of IL-6 in DRG and spinal dorsal horn contributes to neuropathic pain following L5 ventral root transection. Exp. Neurol. 241, 159-168 (2013).
81. Guptarak, J. et al. Inhibition of IL-6 signaling: A novel therapeutic approach to treating spinal cord injury pain. Pain 154, 1115-1128 (2013).
82. DeLeo, J. A., Colburn, R. W., Nichols, M. & Malhotra, A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J. Interferon Cytokine Res. 16, 695-700 (1996).
83. Arruda, J. L., Sweitzer, S., Rutkowski, M. D. & DeLeo, J. A. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: Possible immune modulation in neuropathic pain. Brain Res. 879, 216-225 (2000).
84. Araki, M. et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod. Rheumatol. 23, 827-831 (2013).
85. Ishizu, T. et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128, 988-1002 (2005).
86. Wang, H. et al. Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese-A case control study. J. Neurol. Sci. 314, 26-28 (2012).
87. Wang, H. H. et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 18, 1313-1317 (2011).
88. Wang, K. C. et al. Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 226, 510-516 (2012).
89. Ren, P. C. et al. High-mobility group box 1 contributes to mechanical allodynia and spinal astrocytic activation in a mouse model of type 2 diabetes. Brain Res. Bull. 88, 332-337 (2012).